Eli Lilly and Company $LLY Shares Sold by UMB Bank n.a.

UMB Bank n.a. reduced its position in Eli Lilly and Company (NYSE:LLY) by 9.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 79,786 shares of the company’s stock after selling 8,058 shares during the quarter. Eli Lilly and Company makes up approximately 0.9% of UMB Bank n.a.’s investment portfolio, making the stock its 26th biggest position. UMB Bank n.a.’s holdings in Eli Lilly and Company were worth $60,877,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Dash Acquisitions Inc. lifted its position in Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after acquiring an additional 13 shares in the last quarter. Nvest Financial LLC increased its stake in shares of Eli Lilly and Company by 0.6% in the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock worth $1,773,000 after buying an additional 13 shares during the last quarter. MPS Loria Financial Planners LLC lifted its stake in Eli Lilly and Company by 1.9% during the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock worth $545,000 after purchasing an additional 13 shares during the last quarter. Key Client Fiduciary Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.2% in the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock worth $867,000 after buying an additional 13 shares during the last quarter. Finally, Darwin Wealth Management LLC lifted its holdings in Eli Lilly and Company by 3.6% in the third quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock worth $285,000 after acquiring an additional 13 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.3%

Shares of LLY stock opened at $1,037.84 on Friday. The firm has a market cap of $981.15 billion, a PE ratio of 50.77, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The stock has a 50 day moving average of $1,056.87 and a 200-day moving average of $889.48. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the business posted $1.18 EPS. The business’s quarterly revenue was up 53.9% on a year-over-year basis. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Analyst Ratings Changes

LLY has been the topic of a number of recent research reports. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Leerink Partners set a $1,234.00 target price on Eli Lilly and Company in a report on Monday, January 5th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Wednesday, January 14th. Finally, National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a report on Monday, December 1st. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,162.75.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO David Ricks said impending Medicare coverage for obesity drugs could “change the game” for the launch of Lilly’s oral obesity candidate orforglipron, signaling a major commercial catalyst if access and reimbursement broaden this year. Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch
• Positive Sentiment: Lilly announced a $3.5 billion Lehigh Valley (PA) injectable manufacturing plant to produce next‑gen weight‑loss drugs (including retatrutide), expanding U.S. capacity and creating ~2,800 jobs — a material long‑term supply and growth investment. Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push
• Positive Sentiment: TD Cowen raised its price target sharply to $1,250 and maintained a buy rating, providing analyst backing that can support further upside and investor confidence. TD Cowen adjusts price target on Eli Lilly and Co to $1,250
• Positive Sentiment: Lilly expanded its R&D and partnering footprint with a ~ $1.93B deal with Repertoire (autoimmune therapies) and other gene‑editing/oncology investments, diversifying future growth drivers beyond GLP‑1s. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Neutral Sentiment: Competitor Novo Nordisk ramped U.S. advertising for Wegovy/Ozempic after prior supply constraints eased, outspending Lilly — a sign of intensifying marketing competition in obesity that could pressure share gains or require higher promotional spend. Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases
• Negative Sentiment: The FDA action date for Lilly’s oral weight‑loss pill orforglipron was moved to April 10 (Q2), delaying potential revenue contribution and near‑term clarity on approval — a timing risk that can cap upside until the new decision date. FDA Decision on Eli Lilly’s Weight Loss Pill Delayed to Q2

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.